Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48, Vassileos Constantinou Avenue, 11635, Athens, Greece.
Department of Toxicogenomics, Maastricht University, 6229, Maastricht, ER, Netherlands.
BMC Genomics. 2017 Sep 13;18(1):728. doi: 10.1186/s12864-017-4117-4.
B-cell chronic lymphocytic leukemia (CLL) is a common type of adult leukemia. It often follows an indolent course and is preceded by monoclonal B-cell lymphocytosis, an asymptomatic condition, however it is not known what causes subjects with this condition to progress to CLL. Hence the discovery of prediagnostic markers has the potential to improve the identification of subjects likely to develop CLL and may also provide insights into the pathogenesis of the disease of potential clinical relevance.
We employed peripheral blood buffy coats of 347 apparently healthy subjects, of whom 28 were diagnosed with CLL 2.0-15.7 years after enrollment, to derive for the first time genome-wide DNA methylation, as well as gene and miRNA expression, profiles associated with the risk of future disease. After adjustment for white blood cell composition, we identified 722 differentially methylated CpG sites and 15 differentially expressed genes (Bonferroni-corrected p < 0.05) as well as 2 miRNAs (FDR < 0.05) which were associated with the risk of future CLL. The majority of these signals have also been observed in clinical CLL, suggesting the presence in prediagnostic blood of CLL-like cells. Future CLL cases who, at enrollment, had a relatively low B-cell fraction (<10%), and were therefore less likely to have been suffering from undiagnosed CLL or a precursor condition, showed profiles involving smaller numbers of the same differential signals with intensities, after adjusting for B-cell content, generally smaller than those observed in the full set of cases. A similar picture was obtained when the differential profiles of cases with time-to-diagnosis above the overall median period of 7.4 years were compared with those with shorted time-to-disease. Differentially methylated genes of major functional significance include numerous genes that encode for transcription factors, especially members of the homeobox family, while differentially expressed genes include, among others, multiple genes related to WNT signaling as well as the miRNAs miR-150-5p and miR-155-5p.
Our findings demonstrate the presence in prediagnostic blood of future CLL patients, more than 10 years before diagnosis, of CLL-like cells which evolve as preclinical disease progresses, and point to early molecular alterations with a pathogenetic potential.
B 细胞慢性淋巴细胞白血病(CLL)是一种常见的成人白血病。它通常表现为惰性病程,之前是无症状的单克隆 B 细胞淋巴增生,但尚不清楚是什么原因导致患有这种疾病的人进展为 CLL。因此,预测性标志物的发现有可能改善对可能发展为 CLL 的患者的识别,并且还可能为疾病的发病机制提供潜在的临床相关性见解。
我们利用 347 名看似健康的受试者的外周血白细胞层,其中 28 名在入组后 2.0-15.7 年内被诊断患有 CLL,首次获得与未来疾病风险相关的全基因组 DNA 甲基化、基因和 miRNA 表达谱。在调整白细胞组成后,我们确定了 722 个差异甲基化 CpG 位点和 15 个差异表达基因(Bonferroni 校正 p < 0.05)以及 2 个 miRNA(FDR < 0.05)与未来 CLL 的风险相关。这些信号中的大多数也在临床 CLL 中观察到,这表明在预测性血液中存在 CLL 样细胞。在入组时,B 细胞分数相对较低(<10%)的未来 CLL 病例,因此不太可能患有未确诊的 CLL 或前驱状态,在调整 B 细胞含量后,涉及相同差异信号的数量较少,其强度通常小于在整个病例集中观察到的强度。当将中位时间超过 7.4 年的病例的差异图谱与疾病时间较短的病例进行比较时,也获得了类似的结果。具有主要功能意义的差异甲基化基因包括许多编码转录因子的基因,特别是同源盒家族的成员,而差异表达基因包括多个与 WNT 信号相关的基因以及 miRNA miR-150-5p 和 miR-155-5p。
我们的研究结果表明,在未来的 CLL 患者被诊断出患有疾病超过 10 年前的预测性血液中,存在着 CLL 样细胞,随着临床前疾病的进展,这些细胞会逐渐演变。这表明存在潜在的早期分子改变。